SOHO 2024 live congress feed

Stay up to date with the latest developments in Lymphoma and CLL from the SOHO 2024 Annual Meeting with our live social media coverage.

CONGRESS | #SOHO2024
Izidore Lossos, @univmiami, discusses new agents in marginal zone #lymphoma such as ibrutinib, acalabrutinib, zanabrutinib, umbralisib, parsaclisib, and axi-cel. Upcoming trials at his institution include phase II studies of mosunetuzumab for ND EMZL and… pic.twitter.com/zwwzbM4FNQ

— Lymphoma Hub (@lymphomahub) September 10, 2024

CONGRESS | #SOHO2024@Othman_Al_Sawaf, @UKKoeln, discusses clinical implications of using MRD as a surrogate for PFS or OS. While MRD showed moderate-to-weak correlation with OS and strong correlation with PFS on a trial level, he suggests that MRD shouldn’t be used as a primary… pic.twitter.com/gg6QFY602w

— Lymphoma Hub (@lymphomahub) September 10, 2024

CONGRESS | #SOHO2024@sairah__ahmed, @MDAndersonNews, discussed real world data on CAR T-cell therapy for MCL. Real-world effectiveness & safety of brexu-cel in patients with R/R MCL were similar to ZUMA-2 trial results:
▪️ CIBMTR subgroup analysis by prior treatment: ORR was… pic.twitter.com/R0RWi4l1xy

— Lymphoma Hub (@lymphomahub) September 10, 2024

CONGRESS | #SOHO2024
Reid Merryman, @DanaFarber, discusses evolving role of MRD in #lymphoma and the advancements in cfDNA assays for improving sensitivity of ctDNA detection, including ClonoSeq(R), CAPP-Seq, Avenio, PhaseED-Seq, and MAESTRO. Several clinical trials are adapting… pic.twitter.com/Tml1PRIGvE

— Lymphoma Hub (@lymphomahub) September 10, 2024

CONGRESS | #SOHO2024
Lydia Scarfò, @SanRaffaeleMI, presents an overview of covalent BTKi. Next generation cBTKis, acalabrutinib and zanabrutinib, have improved tolerability profile compared with ibrutinib. In the GIMEMA CLL2121 study in >1200 patients with CLL, 12-m OS was 82.9%… pic.twitter.com/Aerw0HTElA

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024
Lydia Scarfò, @SanRaffaeleMI, presents an overview of covalent BTKi. Next generation cBTKis, acalabrutinib and zanabrutinib, have improved tolerability profile compared with ibrutinib. In the GIMEMA CLL2121 study in >1200 patients with CLL, 12-m OS was 82.9%… pic.twitter.com/Aerw0HTElA

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024 | POSTER@michaelwangmd @MDAndersonNews presents data from the phase III SYMPATICO trial, showing improved safety and efficacy of ibrutinib + venetoclax in patients with R/R MCL and TP53 mutations. N=74, mPFS=20.9, mOS=47.1 mo. #lymphoma #lymsm… pic.twitter.com/Q0kHIXayTJ

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024 | POSTER@DrRaulCordoba @Hospital_FJD presents long-term data from the phase I/II EPCORE NHL-2 trial of epcoritamab + GemOx in a larger cohort of pts with transplant-ineligible R/R #DLBCL, with a focus on complete responders and 2L patients. N=103, ORR were… pic.twitter.com/wb475oUBDC

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024 | POSTER
Lorenzo Falchi @MSKCancerCenter presents data from the phase I/II EPCORE NHL-2 trial of fixed-duration epcoritamab + R2 in 1L FL (updated data from Arm 6) and single-agent epcoritamab as maintenance treatment after SOC in FL (first disclosure of Arm… pic.twitter.com/AZm6OAH8OO

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024 | POSTER
Saurabh Dahiya, Stanford University School of Medicine, presents subgroup analysis by bridging therapy from TRANSCEND FL study of liso-cel as 2L therapy in R/R FL. ORR and CR rates were high and consistent across subgroups; median DOR, PFS, and OS… pic.twitter.com/jiiNY9lua8

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024@StefanBartaMD, @PennMedicine, discusses immunotherapies for T-cell #lymphoma, which are primarily categorized into those targeting surface antigens and those targeting immune checkpoints. He highlights various strategies to overcome the challenges of CAR… pic.twitter.com/sLXKK6sOhq

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024
Frederick Locke, @MoffittNews, talks about CAR T-cell therapy after CAR T-cell therapy for DLBCL. He discusses factors affecting its effectiveness such as immune status within the tumor cells, tumor IFN signaling, suppressive features, target, and the CAR… pic.twitter.com/z57tzjPTIR

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024 | POSTER
William G. Wierda @MDAndersonNews presents exploratory analyses from the TRANSCEND CLL 004 trial of liso-cel in pts with R/R CLL/SLL. Baseline characteristics such as low tumor burden & fewer lines of prior systemic therapies were associated with… pic.twitter.com/NQxZiKqLeJ

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024
Jorge Castillo, @DanaFarber shared insights into management of Waldenström's macroglobulinaemia.
▪️ 80% of patients will need treatment
▪️ Toxicities remain a problem in selecting treatments, which could be managed with dose reduction
▪️ Based on the ASPEN… pic.twitter.com/mKBBauQE0O

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024 | POSTER
William G. Wierda @MDAndersonNews shared results of the BRUIN 1/2 trial of pirtobrutinib in R/R CLL/SLL. N=35, 24 mo PFS was 74.7% & 81.8% (IRC & INV assessed, resp); ORR was 91.4% & 94.3% (IRC & INV assessed, resp). Safety profile was similar to… pic.twitter.com/4NrWqOCnwh

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024 | POSTER
Arnon P. Kater @amsterdamumc shared early results of the EPCORE CLL-1 trial of epcortitamab in Richter's transformation (RT). N=38, mFU=12.9 mo, ORR was 53% (60% & 44% in 1L RT & 2L RT, resp), CR rate was 42% (50% & 33% in 1L RT & 2L RT, resp), mOS… pic.twitter.com/MVm3YxZK3D

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS |#SOHO2024 | POSTER
Santiago Ossorio Prendes at Hospital Universitario Gregorio Marañon, reports 6-year time to next treatment extrapolation curve from the GLOW trial of first-line ibrutinib + venetoclax in elderly/unfit pts with CLL. Projected proportion of patients… pic.twitter.com/XCFoHBt89A

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024
Stephen M Ansell, @MayoClinic, discusses whether ABVD and BEACOPP are still relevant for the treatment of advanced stage Hodgkin #lymphoma. He believes that A(B)VD chemotherapy still has a role for low-risk patients, while younger patients or those with… pic.twitter.com/ka5lMu1N9L

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024@KrishPatelMD, @ProvSwedish, discusses novel investigational agents for the treatment of MCL, such as molecular glues/degraders, ADCs, novel CAR T cells, and BsAbs. Notable “off the shelf” therapies with meaningful activity include glofitimab monotherapy and… pic.twitter.com/vsVb5bgPuY

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024
Craig Portell, @UVACancerCenter, discusses sequencing therapies in R/R MCL. He advises considering prior exposure to BTKi when managing relapse in MCL. If the patient hasn't been previously exposed, a BTKi should be started. If they’re actively on a BTKi at… pic.twitter.com/TccEL2LdWM

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024
Nina Wagner Johnston, @HopkinsMedicine, discusses the role of BTKi in frontline treatment of MCL. In older patients, addition of continuous ibrutinib to bendamustine and rituximab (BR) improved PFS however, worsened OS due to toxicity, while continuous… pic.twitter.com/KGvo5zQ1hB

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024
Christopher Yasenchak, Willamette Valley Cancer Institute, shares results from the phase III ECHELON-3 study of brentuximab vedotin in combination with len and rituximab for R/R DLBCL.
Median PFS 4.2 mo, OS 13.8 mo, ORR 64%, CR 40%, AEs were managed with dose… pic.twitter.com/vQ6hK7km2A

— Lymphoma Hub (@lymphomahub) September 6, 2024

CONGRESS | #SOHO2024
Jason Westin @Lymphoma_Doc @MDAndersonNews shares data from the phase Ib trial of GOLCA+R-CHOP as 1L therapy in aggressive B-cell #lymphoma. ORR 0.2mg 82% and 0.4mg 88%, uMRD 0.2mg 73% and 0.4mg 90%, median DoR NR in either group, 12-mo PFS 0.4mg 85%, 120-mo… pic.twitter.com/uPhpTo9lZX

— Lymphoma Hub (@lymphomahub) September 6, 2024

CONGRESS | #SOHO2024@AstridPavlovsky, Fundaleu, Buenos Aires, discusses accessing novel therapies for aggressive lymphoma; concluding that while there are significant advances in the management of lymphomas, there remains discrepancies in access to novel therapies and clinical… pic.twitter.com/DDEJpuA4il

— Lymphoma Hub (@lymphomahub) September 6, 2024

CONGRESS | #SOHO2024@gilles_salles @MSKCancerCenter discusses how to sequence therapies in R/R DLBCL, with the aim to optimize the chance of cure; concluding with a look to the future landscape and the possibility of achieving a cure amongst a substantial fraction of patients.… pic.twitter.com/wqZN2SS7sd

— Lymphoma Hub (@lymphomahub) September 6, 2024

CONGRESS | #SOHO2024
William Wierda, @MDAndersonNews, discusses whether continuous therapy is the best option for high-risk pts with CLL. In pts with del(17p)/TP53 mutations, second generation covalent BTK inhibitors (such as ibrutinib) show median PFS of 6+ years, however, are… pic.twitter.com/vAmatBsYuy

— Lymphoma Hub (@lymphomahub) September 6, 2024

CONGRESS | #SOHO2024
William Wierda, @MDAndersonNews, presents post hoc exploratory analysis results of the phase I/II TRANSCEND CLL 004 study evaluating characteristics associated with response to liso-cel in pts with R/R CLL/SLL (n=87). OR and CR rates did not correlate with… pic.twitter.com/iOwOwwnxA3

— Lymphoma Hub (@lymphomahub) September 6, 2024

CONGRESS | POSTER | #SOHO2024 |
Tamar Tadmor @TadmorTamar presents the phase III BELLWAVE-011 study which will investigate nemtabrutinib vs ibrutinib or acalabrutinib in pts with treatment-naïve CLL/SLL (N=1,200). Primary objectives are to evaluate ORR and PFS, with secondary… pic.twitter.com/eTapscE0Xf

— Lymphoma Hub (@lymphomahub) September 4, 2024

CONGRESS | POSTER | #SOHO2024 |
Ning Dong @NingDong9 presents single center experience of SoC epcoritamab for R/R #LBCL (N=26). In this heavily pretreated population, the CR rate was 18.9% at median follow-up of 4 months, with PR in 31.8%. #lymphoma #lymsm #MedicalCongress pic.twitter.com/bPZ8sIw2zt

— Lymphoma Hub (@lymphomahub) September 4, 2024

CONGRESS | POSTER | #SOHO2024 | Yasmin Karimi @Yhkarimi presents extended follow-up data beyond 2.5 years from the pivotal expansion cohort of the phase II EPCORE NHL-1 study of epcoritamab monotherapy in R/R #DLBCL (N=157). Of pts with a CR (n=65) 54% remained in CR at 30… pic.twitter.com/mkTvkPIput

— Lymphoma Hub (@lymphomahub) September 4, 2024

CONGRESS | POSTER | #SOHO2024 | Martin Hutchings @DocHutchings presents extended follow-up from a pivotal phase II study of glofitamab monotherapy in pts with R/R #DLBCL (N=155) and subgroup analysis in pts with prior CAR-T cell therapy (N=52). Overall ORR was 52% with overall CR… pic.twitter.com/m5DMB3SQwN

— Lymphoma Hub (@lymphomahub) September 4, 2024

CONGRESS | POSTER | #SOHO2024 | Daniel Kerr presents first results from the phase Ib/II EPCORE NHL-5 study investigating subcutaneous epcoritamab + pola-R-CHP as 1L treatment for #DLBCL (N=37). The ORR was 100% with CR 89%, demonstrating that epcoritamab can be combined with 1L… pic.twitter.com/9hGxqQxpNt

— Lymphoma Hub (@lymphomahub) September 4, 2024

CONGRESS | POSTER | #SOHO2024 | Stephen Schuster @Penn presented 3-year follow-up updates from a pivotal phase II study of mosenutuzumab in heavily pretreated R/R FL (N=90). Long-lasting remissions were achieved, with 3-year PFS and OS stable and estimated 30-month DOR rate 72.7%… pic.twitter.com/S00booYr00

— Lymphoma Hub (@lymphomahub) September 4, 2024